Inventor · disambiguated record
David Chaplin
Also filed as: CHAPLIN DAVID · CHAPLIN DAVID J · EDVARDSEN KLAUS
18 granted patents·16 pending applications·192 citations·filing 1987–2022
94Inventor score
Top patents by PatentIndex Score
34 records- 0193US4921963APlatinum complexes with one radiosensitizing ligandBRITISH COLUMBIA CANCER FOUNDA·Filed 1987·Granted May 1, 1990·73 cites·13 claims
- 0290US5026694APlatinum complexes with one radiosensitizing ligandBRITISH COLUMBIA CANCER FOUNDA·Filed 1989·Granted Jun 25, 1991·44 cites·30 claims
- 0385US6919324B2Functionalized stilbene derivatives as improved vascular targeting agentsUNIV BAYLOR·Filed 2002·Granted Jul 19, 2005·19 cites·12 claims
- 0483US7384925B2Functionalized stilbene derivatives as improved vascular targeting agentsOXIGENE INC·Filed 2005·Granted Jun 10, 2008·6 cites·8 claims
- 0579US7001926B2Tubulin binding agents and corresponding prodrug constructsUNIV BAYLOR·Filed 2003·Granted Feb 21, 2006·10 cites·28 claims
- 0677US8877967B2Compositions and methods for inhibition of cathepsinsOXIGENE INC·Filed 2013·Granted Nov 4, 2014·4 cites·20 claims
- 0774US7358236B1Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agentsOXIGENE INC·Filed 2003·Granted Apr 15, 2008·5 cites·13 claims
- 0873US9458103B2Compositions and methods for inhibition of cathepsinsOXIGENE INC·Filed 2014·Granted Oct 4, 2016·2 cites·8 claims
- 0973US7456214B2Chromene-containing compounds with anti-tubulin and vascular targeting activityUNIV BAYLOR·Filed 2004·Granted Nov 25, 2008·7 cites·20 claims
- 1070US9873668B2Compositions and methods for inhibition of cathepsinsMATEON THERAPEUTICS INC·Filed 2016·Granted Jan 23, 2018·2 cites·29 claims
- 1170US9040500B2Method for treating hematopoietic neoplasmsCHAPLIN DAVID·Filed 2011·Granted May 26, 2015·2 cites·11 claims
- 1269US7091240B2Tubulin binding ligands and corresponding prodrug constructsUNIV BAYLOR·Filed 2003·Granted Aug 15, 2006·3 cites·28 claims
- 1367US2009258937A1Methods for Modulating Tumor Growth and MetastasisLEE FRANCIS Y·Filed 2008·Application pending·0 cites
- 1465US8198302B2Compositions and methods with enhanced therapeutic activityCHAPLIN DAVID J·Filed 2004·Granted Jun 12, 2012·3 cites·8 claims
- 1563US2009192098A1Method for treating hematopoietic neoplasmsOXIGENE INC·Filed 2008·Application pending·0 cites
- 1661USRE45720EFunctionalized stilbene derivatives as improved vascular targeting agentsOXIGENE INC·Filed 2014·Granted Oct 6, 2015·0 cites·12 claims
- 1760US2022401556A1Use of vdas to enhance immunomodulating therapies against tumorsONCOTELIC THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1859USRE45907EFunctionalized stilbene derivatives as improved vascular targeting agentsOXIGENE INC·Filed 2014·Granted Mar 1, 2016·0 cites·8 claims
- 1959US2009264382A1Methods for Treating Hematopoietic NeoplasmsCHAPLIN DAVID·Filed 2008·Application pending·0 cites
- 2054US6028111ACompositions and use of benzamides and nicotinamides as anti-inflammatory agentsOXIGENE INC·Filed 1997·Granted Feb 22, 2000·11 cites·10 claims
- 2150US2005209310A1Methods for modulating tumor growth and metastasisCHAPLIN DAVID J·Filed 2004·Application pending·0 cites
- 2250US2006135625A1Method of administering split doses of a vascular targeting agentCHAPLIN DAVID J·Filed 2006·Application pending·0 cites
- 2350US2006194770A1Methods for modulating tumor growth and metastasisLEE FRANCIS Y·Filed 2006·Application pending·0 cites
- 2449US11419934B2Use of VDAS to enhance immunomodulating therapies against tumorsONCOTELIC THERAPEUTICS INC·Filed 2016·Granted Aug 23, 2022·0 cites·5 claims
- 2549US2004067255A1Method of administering split doses of a vascular targeting agentFiled 2002·Application pending·0 cites
- 2646US2006100179A1Compositions and methods for use in targeting vascular destructionPERO RONALD W·Filed 2005·Application pending·0 cites
- 2744US2015246064A1Method for treating hematopoietic neoplasmsCHAPLIN DAVID·Filed 2015·Application pending·0 cites
- 2844US2009209496A1Methods and compositions for enhancing the efficacy of rtk inhibitorsCHAPLIN DAVID·Filed 2009·Application pending·0 cites
- 2943US2015141349A1Method and Composition for Alleviating Tumor SymptomsANGIOGENE PHARM LTD·Filed 2013·Application pending·0 cites
- 3042US2006142252A1Tubulin binding agents and corresponding prodrug constructsPINNEY KEVIN G·Filed 2006·Application pending·0 cites
- 3142US2009137687A1Compositions and Methods With Enhanced Therapeutic ActivityOXIGENE INC·Filed 2008·Application pending·0 cites
- 3233US2005245489A1Chromene-containing compounds with anti-tubulin and vascular targeting activityPINNEY KEVIN G·Filed 2004·Application pending·0 cites
- 3330US6713517B1Use of aryl N-substituted carboxamides directly and as radio-and chemosensitizers for killing tumor and cancer cells and novel compounds for such useOXIGENE INC·Filed 1997·Granted Mar 30, 2004·1 cites·3 claims
- 3430US2019010173A1Compositions and methods for inhibition of cathepsinsMATEON THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Chaplin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →